GoAI
Get started
Annovis Bio, Inc. logo

Annovis Bio, Inc.

ANVS

NYSEHealthcareBiotechnology

Open in GoAI

Previous close

$1.82

+$0.03 · +1.68%

Aug 21, 4:00 PM ET

ANVS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

26

Expensive

Momentum

26

Weakening

Sentiment

54

Mixed

Risk resilience

30

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Maria L. Maccecchini
Listed since
Jan 29, 2020
Employees
7

Market position

Day range

Current $1.82

52-week range

Current $1.82

Open
$1.82
Previous close
$1.79
Volume
609.24K
0.64× average
Average volume
948.5K
Average daily volume
Market cap
77.43M USD
Beta
1.24
Market reference 1
50-day average
$1.797
+1.28% above average
200-day average
$2.4885
-26.86% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
51.58M USD
EV / EBITDA
-1.79×
Earnings yield
-40.58%
Free cash flow yield
-36028.31%

Profitability & efficiency

Return on equity
-171.23%
Return on assets
-136.87%
Return on invested capital
-170.21%

Financial health

Current ratio
5.8×

Financial statements

Income trends

Operating income

−29.7M USD-11.24%

Net income

−28.85M USD-17.34%
Income trends across reported periods−10.32M USD−27M USD−43.69M USD−60.38M USDOperating income, FY2021: −14.54M USDOperating income, FY2022: −25.51M USDOperating income, FY2023: −45.04M USDOperating income, FY2024: −26.69M USDOperating income, FY2025: −29.7M USDNet income, FY2021: −14.49M USDNet income, FY2022: −25.33M USDNet income, FY2023: −56.2M USDNet income, FY2024: −24.59M USDNet income, FY2025: −28.85M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −14.54M USD. Operating income FY2022 −25.51M USD. Operating income FY2023 −45.04M USD. Operating income FY2024 −26.69M USD. Operating income FY2025 −29.7M USD. Net income FY2021 −14.49M USD. Net income FY2022 −25.33M USD. Net income FY2023 −56.2M USD. Net income FY2024 −24.59M USD. Net income FY2025 −28.85M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development25.22M USD20M USD38.79M USD16.52M USD8.48M USD
Selling, general, and administrative4.48M USD6.7M USD6.24M USD9M USD6.06M USD
Operating expenses29.7M USD26.69M USD45.04M USD25.51M USD14.54M USD
Interest income699.06K USD331.85K USD667.9K USD182.71K USD13.34K USD
Interest expense—1.85M USD———
Operating income−29.7M USD−26.69M USD−45.04M USD−25.51M USD−14.54M USD
Net income−28.85M USD−24.59M USD−56.2M USD−25.33M USD−14.49M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-13.65%
11 comparable reports
Latest EPS result
-0.4
Estimate -0.45 · Beat by 11.76%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.26-0.4-0.53-0.67Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 21, 2025: actual -0.43, estimate -0.38, surprise -13.16%, Miss. Q2 2025, reported May 13, 2025: actual -0.32, estimate -0.47, surprise +31.91%, Beat. Q3 2025, reported Aug 12, 2025: actual -0.32, estimate -0.36, surprise +11.11%, Beat. Q4 2025, reported Nov 12, 2025: actual -0.37, estimate -0.36, surprise -2.78%, Miss. Q1 2026, reported Mar 16, 2026: actual -0.39, estimate -0.308, surprise -26.46%, Miss. Q2 2026, reported May 15, 2026: actual -0.63, estimate -0.395, surprise -59.49%, Miss. Q3 2026, reported Aug 14, 2026: actual -0.4, estimate -0.453, surprise +11.76%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.3, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$25.67

1310.44% upside
Past 12 months12-month forecastHigh $30.00Average $25.67Low $21.00

Recent analyst actions

7 institutions
Maxim GroupupgradeHoldBuy
EF HuttonmaintainBuy
Rodman & RenshawmaintainBuy
Brookline CapitaldowngradeBuyHold

ANVS peers

Eli Lilly and Company logo

LLY

Eli Lilly and Company

$1,254.77

+0.83%

Johnson & Johnson logo

JNJ

Johnson & Johnson

$270.24

+1.07%

AbbVie Inc. logo

ABBV

AbbVie Inc.

$265.01

+1.21%

Merck & Co., Inc. logo

MRK

Merck & Co., Inc.

$152.55

+2.39%

UnitedHealth Group Incorporated logo

UNH

UnitedHealth Group Incorporated

$390.11

+1.37%

Novartis AG logo

NVS

Novartis AG

$158.86

+1.68%

ETFs holding ANVS

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
2.13M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
689.3K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
187.4K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research ANVS

research.disclaimer